Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | F2 | P00734 | 7/20 | 0.57 |
| ▸ | MAPT | P10636 | 6/20 | 0.54 |
| ▸ | THRB | P10828 | 2/20 | 0.54 |
| ▸ | KLKB1 | P03952 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | KLK1 | P06870 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.48 |
| ▸ | CDK2 | P24941 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2561284 | 0.98 | GAA (0.61) | GAAF2MAPTTHRBKLKB1 | |
| SCHEMBL2564484 | 0.94 | F2 (0.60) | GAAF2MAPTTHRBKLKB1 | |
| SCHEMBL2565228 | 0.93 | F2 (0.54) | GAAF2MAPTTHRBKLKB1 | |
| SCHEMBL2567902 | 0.91 | F2 (0.57) | GAAF2MAPTTHRBKLKB1 | |
| SCHEMBL2569730 | 0.90 | F2 (0.58) | GAAF2MAPTTHRBKLKB1 | |
| SCHEMBL2564273 | 0.90 | F2 (0.58) | GAAF2MAPTTHRBKLKB1 | |
| SCHEMBL2569658 | 0.90 | F2 (0.60) | GAAF2MAPTTHRBKLKB1 | |
| SCHEMBL14688731 | 0.88 | MAPT (0.72) | GAAF2MAPTTHRBKLKB1 | |
| SCHEMBL14687550 | 0.88 | MAPT (0.72) | GAAF2MAPTTHRBKLKB1 | |
| SCHEMBL28016243 | 0.88 | MAPT (0.56) | GAAF2MAPTTHRBKLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2560966-B1 | MULTISUBSTITUTED AROMATIC COMPOUNDS AS INHIBITORS OF THROMBIN | VERSEON INT CORPORATION (US) | 2021-01-06 | — | — | EP | claimed |
| US-9533967-B2 | Multisubstituted aromatic compounds as inhibitors of thrombin | VERSEON CORPORATION (US) | 2017-01-03 | — | — | US | claimed |
| CN-102918034-B | Polysubstituted aromatic compounds as inhibitors of thrombin | VERSEON CORP | 2015-06-03 | — | — | CN | claimed |
| EP-2560966-B1 | MULTISUBSTITUTED AROMATIC COMPOUNDS AS INHIBITORS OF THROMBIN | VERSEON INT CORPORATION (US) | 2021-01-06 | — | — | EP | disclosed |
| US-10653674-B2 | Multisubstituted aromatic compounds as inhibitors of thrombin | VERSEON CORPORATION (US) | 2020-05-19 | — | — | US | disclosed |
| US-20180214418-A1 | MULTISUBSTITUTED AROMATIC COMPOUNDS AS INHIBITORS OF THROMBIN | VERSEON INTERNATIONAL CORPORATION | 2018-08-02 | — | — | US | disclosed |
| US-9963440-B2 | Multisubstituted aromatic compounds as inhibitors of thrombin | VERSEON CORPORATION (US) | 2018-05-08 | — | — | US | disclosed |
| US-20170326125-A1 | MULTISUBSTITUTED AROMATIC COMPOUNDS AS INHIBITORS OF THROMBIN | VERSEON INTERNATIONAL CORPORATION | 2017-11-16 | — | — | US | disclosed |
| US-9533967-B2 | Multisubstituted aromatic compounds as inhibitors of thrombin | VERSEON CORPORATION (US) | 2017-01-03 | — | — | US | disclosed |
| US-20160256440-A1 | MULTISUBSTITUTED AROMATIC COMPOUNDS AS INHIBITORS OF THROMBIN | VERSEON INTERNATIONAL CORPORATION | 2016-09-08 | — | — | US | disclosed |
| US-20160136177-A1 | MULTISUBSTITUTED AROMATIC COMPOUNDS AS INHIBITORS OF THROMBIN | VERSEON INTERNATIONAL CORPORATION | 2016-05-19 | — | — | US | disclosed |
| US-20160122333-A1 | MULTISUBSTITUTED AROMATIC COMPOUNDS AS INHIBITORS OF THROMBIN | VERSEON INTERNATIONAL CORPORATION | 2016-05-05 | — | — | US | disclosed |
| EP-2560966-A2 | MULTISUBSTITUTED AROMATIC COMPOUNDS AS INHIBITORS OF THROMBIN | Verseon Corporation (US) | 2013-02-27 | — | — | EP | disclosed |
| US-20130040950-A1 | MULTISUBSTITUTED AROMATIC COMPOUNDS AS INHIBITORS OF THROMBIN | VERSEON CORPORATION (US) | 2013-02-14 | — | — | US | disclosed |
| WO-2011126903-A2 | MULTISUBSTITUTED AROMATIC COMPOUNDS AS INHIBITORS OF THROMBIN | VERSEON, INC. (US) | 2011-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160256440-A1 | MULTISUBSTITUTED AROMATIC COMPOUNDS AS INHIBITORS OF THROMBIN | TFPI, PLAT, SERPINC1 | GAA 569/4885F2 4/4885MAPT 1854/4885 |
| US-20170326125-A1 | MULTISUBSTITUTED AROMATIC COMPOUNDS AS INHIBITORS OF THROMBIN | TFPI, PLAT, SERPINC1 | GAA 569/4885F2 4/4885MAPT 1854/4885 |
| US-20180214418-A1 | MULTISUBSTITUTED AROMATIC COMPOUNDS AS INHIBITORS OF THROMBIN | TFPI, PLAT, SERPINC1 | GAA 569/4885F2 4/4885MAPT 1854/4885 |
| US-20160122333-A1 | MULTISUBSTITUTED AROMATIC COMPOUNDS AS INHIBITORS OF THROMBIN | TFPI, PLAT, SERPINC1 | GAA 569/4885F2 4/4885MAPT 1854/4885 |
| US-10653674-B2 | Multisubstituted aromatic compounds as inhibitors of thrombin | TFPI, PLAT, SERPINC1 | GAA 569/4885F2 4/4885MAPT 1854/4885 |
| US-20160136177-A1 | MULTISUBSTITUTED AROMATIC COMPOUNDS AS INHIBITORS OF THROMBIN | TFPI, PLAT, SERPINC1 | GAA 569/4885F2 4/4885MAPT 1854/4885 |
| US-20130040950-A1 | MULTISUBSTITUTED AROMATIC COMPOUNDS AS INHIBITORS OF THROMBIN | TFPI, PLAT, SERPINC1 | GAA 569/4885F2 4/4885MAPT 1854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.